

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/00, C12Q 1/00, C07K 7/06, 7/08		A2	(11) International Publication Number: WO 97/08304
			(43) International Publication Date: 6 March 1997 (06.03.97)
(21) International Application Number: PCT/IT96/00163		(81) Designated States: AU, BR, CA, CN, JP, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 20 August 1996 (20.08.96)			
(30) Priority Data: RM95A000573 22 August 1995 (22.08.95) IT		Published Without international search report and to be republished upon receipt of that report.	
(71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. [IT/IT]; Via Pontina, Km 30.600, I-00040 Pomezia (IT).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): STEINKÜHLER, Christian [DE/IT]; Via delle Mimose, I-00061 Anguillara (IT). PESSI, Antonello [IT/IT]; Via Montebianco, 63, I-00141 Roma (IT). BIANCHI, Elisabetta [IT/IT]; Via Sabotino, 31, I-00195 Roma (IT). TALIANI, Marina [IT/IT]; Via Curzio Rufo, 15, I-00174 Roma (IT). TOMEI, Licia [IT/IT]; Via Gadda, 173, I-00143 Roma (IT). URBANI, Andrea [IT/IT]; Via Piave, 41, I-00187 Roma (IT). DE FRANCESCO, Raffaele [IT/IT]; Via Devich, 46, I-00143 Roma (IT). NARJES, Frank [DE/IT]; Via Ramo d'Oro, 53, I-00040 Ariccia (IT).			
(74) Agents: DI CERBO, Mario et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT).			

(54) Title: METHODOLOGY TO PRODUCE, PURIFY AND ASSAY POLYPEPTIDES WITH THE PROTEOLYTIC ACTIVITY OF THE HCV NS3 PROTEASE



(57) Abstract

The process according to the present invention allows expression and isolation of polypeptides with the proteolytic activity of HCV NS3 protease in a pure, catalytically active form, and in amounts that are sufficient for discovery of NS3 protease inhibitors and for determination of the three-dimensional structure of the NS3 protease. A further subject of the present invention is a procedure that defines the chemical and physical conditions necessary for completion of the proteolytic activity of the above polypeptides. The invention further comprises new compositions of matter (expression vectors) containing nucleotide sequences capable of expressing the above mentioned polypeptides in culture cells. Finally, new compounds of matter are defined, suitable to measure the above proteolytic activity, and useful to develop NS3 protease inhibitors and therefore therapeutic agents for use against HCV. The figure shows the kinetic parameters of HCV NS3 protease using the S3 depsiptide substrate (SEQ ID NO:45).

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHODOLOGY TO PRODUCE, PURIFY AND ASSAY POLYPEPTIDES  
WITH THE PROTEOLYTIC ACTIVITY OF THE HCV NS3 PROTEASE

DESCRIPTION

5       The present invention relates to molecular biology  
and to hepatitis C virus (HCV) virology. More  
specifically, the invention has as its subject a process  
for producing, in a pure form and in high quantities,  
polypeptides having the proteolytic activity of HCV NS3  
10       protease, and a method for the effective reproduction in  
vitro of the proteolytic activity of these polypeptides  
in order to define an enzymatic assay capable of  
selecting, for therapeutic purposes, compounds inhibiting  
the enzyme activity associated with NS3.

15       As is known, the hepatitis C virus (HCV) is the main  
etiological agent of non-A, non-B hepatitis (NANB). It is  
estimated that HCV causes at least 90% of post-  
transfusional NANB viral hepatitis and 50% of sporadic  
NANB hepatitis. Although great progress has been made in  
the selection of blood donors and in the immunological  
20       characterisation of blood used for transfusions, there is  
still a high number of HCV infections among recipients of  
blood transfusions (one million or more infections every  
year throughout the world). Approximately 50% of HCV-  
infected individuals develop liver cirrhosis within a  
25       period that can range from 5 to 40 years. Furthermore,  
recent clinical studies suggest that there is a  
correlation between chronic HCV infection and the  
development of hepatocellular carcinoma.

30       HCV is an enveloped virus containing an RNA positive  
genome of approximately 9.4 kb. This virus is a member of  
the Flaviviridae family, the other members of which are  
the flaviviruses and the pestiviruses.

35       The RNA genome of HCV has recently been mapped.  
Comparison of sequences from the HCV genomes isolated in  
various parts of the-world has shown that these sequences  
can be extremely heterogeneous. The majority of the HCV  
genome is occupied by an open reading frame (ORF) that

can vary between 9030 and 9099 nucleotides. This ORF codes for a single viral polyprotein, the length of which can vary from 3010 to 3033 amino acids. During the viral infection cycle, the polyprotein is proteolytically processed into the individual gene products necessary for replication of the virus.

The genes coding for HCV structural proteins are located at the 5'-end of the ORF, whereas the region coding for the non-structural proteins occupies the rest of the ORF.

The structural proteins consist of C (core, 21 kDa), E1 (envelope, gp37) and E2 (NS1, gp61). C is a non-glycosylated protein of 21 kDa which probably forms the viral nucleocapsid. The protein E1 is a glycoprotein of approximately 37 kDa, which is believed to be a structural protein for the outer viral envelope. E2, another membrane glycoprotein of 61 kDa, is probably a second structural protein in the outer envelope of the virus.

The non-structural region starts with NS2 (p24), a hydrophobic protein of 24 kDa whose function is unknown.

NS3, a protein of 68 kDa which follows NS2 in the polyprotein, is predicted to have two functional domains: a serine protease domain within the first 200 amino-terminal amino acids, and an RNA-dependent ATPase domain at the carboxy terminus.

The NS4 gene region codes for NS4A (p6) and NS4B (p26), two hydrophobic proteins of 6 and 26 kDa, respectively, whose functions have not yet been fully clarified.

The NS5 gene region also codes for two proteins, NS5A (p56) and NS5B (p65), of 56 and 65 kDa, respectively. Amino acid sequences present in all the RNA-dependent RNA polymerases can be recognised within the NS5 region. This suggests that the NS5 region contains components of the viral replication machinery.

Various molecular biological studies indicate that the signal peptidase, a protease associated with the endoplasmic reticulum of the host cell, is responsible for proteolytic processing in the non-structural region, that is to say at sites C/E1, E1/E2 and E2/NS2.

The serine protease in NS3 is responsible for cleavage at the junctions between NS3 and NS4A, between NS4A and NS4B, between NS4B and NS5A and between NS5A and NS5B. In particular it has been found that the cleavage made by this serine protease leaves a cysteine or a treonine residue on the amino-terminal side (position P1) and an alanine or serine residue on the carboxy-terminal side (position P1') of the cleavage site. It has been shown that the protease contained in NS3 is a heterodimeric protein in vivo, forming a complex with the protein NS4A. Formation of this complex increases proteolytic activity on sites NS4A/NS4B and NS5A/NS5B, and is a necessary requisite for proteolytic processing of site NS4B/NS5A.

A second protease activity of HCV appears to be responsible for the cleavage between NS2 and NS3. This protease activity is contained in a region comprising both part of NS2 and the portion of NS3 containing the serine protease domain, but does not use the same catalytic mechanism as the latter.

A substance capable of interfering with the proteolytic activity associated with the protein NS3 might constitute a new therapeutic agent. In effect, inhibition of this protease activity would involve stopping the proteolytic processing of the non-structural region of the HCV polyprotein and, consequently, would prevent viral replication of the infected cells.

This sequence of events has been verified for the homologous flavivirus, which, unlike HCV, infects cell line cultures. In this case, it has been shown that genetic manipulations involving generation of a protease

no longer capable of carrying out its catalytic activity, abolishes the ability of the virus to replicate (1).

Furthermore, it has been widely shown, both in vitro and in clinical studies, that compounds capable of interfering with the HIV protease activity are capable of inhibiting replication of this virus (2).

The methods used to generate molecules with therapeutic potential are known to those operating in this field. Generally speaking, collections of compounds containing a large number of single chemical entities with a high molecular diversity are made to undergo an automatised assay in order to identify single active agents, which then undergo further chemical modifications in order to improve their therapeutic potential. Other approaches may include rational modification of substrates or ligands of specific target protein, with the aim of developing high binding affinity compounds capable of altering or abolishing the biological activity of the protein under examination. Determination of the three-dimensional structure of a target protein, by means of methods known in the sector as X-ray crystallography or nuclear magnetic resonance (NMR) allows rational design of molecules capable of binding specifically to the protein and which, as a result of this, have the ability to interfere with the biological properties of that protein.

Research on compounds capable of interfering with the biological activity of the protease contained in the hepatitis C virus NS3 protein is hampered by the difficulty in producing sufficient amounts of purified protein with unaltered catalytic properties, and by the need to use co-factors to enhance the activity of the enzyme in vitro.

There is therefore a need in the specific field for a process to produce NS3, or similar products, in larger amounts that has been possible in the past, and with an in vitro activity sufficient to select inhibitors.

The present invention consists of isolated and purified polypeptides, with the proteolytic activity of the HCV protein NS3, characterised by the fact that they have an amino acid sequence chosen from among the sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.

The invention also comprises expression vectors - to produce the polypeptides represented by sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 which have the proteolytic activity of HCV NS3 - comprising:

- a polynucleotide coding for one of said polypeptides;
- functional regulation, transcription and translation sequences in said host cell, operatively bonded to said polynucleotide coding for one of said polypeptides; and
- optionally, a selectable marker.

The invention also extends to a host cell, either eukaryotic or prokaryotic, transformed using an expression vector containing a DNA sequence coding for SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 in such a way as to allow said host cell to express the specific coded polypeptide in the chosen sequence. The invention further comprises a process for preparation of polypeptides with sequence selected from the group comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, characterised by the fact that it comprises, in combination, the following operations:

- transformation of a host cell, either eukaryotic or prokaryotic, using one of the expression vectors mentioned above; and
- expression of the desired nucleotide sequence to produce the chosen polypeptide; and
- purification of the polypeptide thus obtained, avoiding resolubilisation protocols.

The present invention also has as its object a method for reproducing in vitro the proteolytic activity of the HCV NS3 protease, characterised by the fact that the activity of purified polypeptides, with sequences  
5 chosen from the group comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, similar to NS3, is reproduced in a solution containing 30-70 mM Tris pH 6.5-8.5, 3-30 mM dithiotreitol (DTT), 0.5-3% 3-[(3-colammide-propyl)-dimethyl-ammonium]-1-  
10 propansulphonate (CHAPS) and 30-70% glycerol at temperatures of between 20 and 25°C and by the fact that in these conditions the activity of the above mentioned polypeptides can be kinetically determined and quantified on peptide substrates even in the absence of co-factors.

15 An assay of the protease activity of the polypeptides SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 can be performed by cleaving a substrate providing detectable products. The cleavage is preferably detected using methods based on radioactive,  
20 colorimetric or fluorimetric signals. Methods such as HPLC and the like are also suitable. According to the present invention, the substrates used are synthetic peptides corresponding to the HCV polyprotein NS4A/4B junction. If necessary, peptides containing the amino  
25 acid sequence SEQ ID NO:6, or parts thereof, can be used as co-factor of the NS3 protease.

Peptides suitable for use as substrates are the peptide represented by the sequence SEQ ID NO:7 and derivatives thereof with N and/or C-terminal deletions  
30 (SEQ ID NOS:8-12, 14, 18-20) and the peptide represented by the sequence SEQ ID NO:47. Particularly suitable are the decapeptides represented by the sequences SEQ ID NOS:18-20, especially SEQ IS NO:18 and the sequences derived therefrom SEQ ID NOS:29-32, 35.

35 These peptides can be used for a high-throughput assay of NS3 protease activity at a concentration of the latter of between 100-200 nM.



According to the invention depsipeptide substrates (peptides with at least one ester bond in the sequences) can also be used advantageously for a high-throughput assay of the activity of the NS3 protease. It is, in fact, known that it is desirable to run the assay at the lowest possible enzyme concentration compatible with sufficient substrate conversion. This maximises sensitivity to inhibition and allows to screen for inhibitors which are present at very low concentrations in compound mixtures or combinatorial libraries. Substrates for NS3 protease with a standard amide at the scissile bond between residues P1 and P1' have  $K_{cat}/K_m$  values between 30-100  $M^{-1} s^{-1}$ . This sets a practical range of enzyme concentration for a high-throughput assay of 100-200 nM. To lower this concentration it is necessary to use substrates with higher  $K_{cat}/K_m$  values. Substrates containing an ester bond between P1 and P1' are ideally suited for this, since formation of the acyl-enzyme intermediate is accomplished much more readily due to the more thermodynamically favourable transesterification reaction (8). The depsipeptide substrates according to the invention have very high  $K_{cat}/K_m$  values, and this brings the useful range of NS3 concentration in the high-throughput assay to 0.5-2 nM. These substrates may be synthesised in high yield on solid-phase by standard chemical methodology.

Conventional assays are suitable for high throughput screening, but they require hydrolysis of at least 10% of the substrate before the product can be detected conveniently. This precludes determination of true initial rates, which are important for accurate kinetic studies. To overcome these difficulties, an assay has been developed that allows continuous monitoring of protease activity. The assay relies on specially tailored synthetic substrates, which are capable of direct, continuous signal generation that is directly proportional to the extent of substrate hydrolysis, thus

avoiding the need for separation of the substrate from the reaction product. The depsipeptides used (SEQ ID NOS:45 and 46), the chemical formulas of which are given in figure 12, are internally quenched fluorogenic substrates based on resonance energy transfer (RET). They contain a fluorescent donor, 5-[(2'-aminoethyl)amino]naphthalenesulfonic acid (EDANS), near one end of the peptide, and an acceptor group, 4-[[4'-(dimethylamino)phenyl]azo]benzoic acid (DABCYL) near the other end. The fluorescence of this type of substrate is initially quenched by intramolecular RET between the donor and the acceptor, but as the enzyme cleaves the substrate the fluorescence increases. EDANS and DABCYL were selected as donor/acceptor pair because of the excellent spectral overlap between the fluorescent emission of the former and the absorption of the latter (13-17). RET efficiency depends on the distance between the donor and the acceptor, i.e. the closer the two, the higher the quenching. For the EDANS/DABCYL couple, the Förster distance for 50% energy-transfer ( $R_0$ ) is 33 Å. The maximum distance between EDANS/DABCYL reported in a substrate is 11 amino acids (19) which, assuming an extended conformation for the peptide, corresponds to  $R=39.8$  Å, with a calculated RET efficiency of 24.5%. This corresponds to a 10-fold increase in fluorescence upon substrate cleavage.

Up to this point a general description has been given of the present invention. With the aid of the following examples, a more detailed description of specific embodiments thereof will now be given, in order to give a better understanding of the aims, characteristics, advantages and operation methods of the invention.

Figure 1 shows the plasmid vector used for transfer and expression of the polypeptide represented by SEQ ID NO:1 in *Spodoptera frugiperda* clone 9 cells.

Figures 2A and 2B show the plasmid vectors for transfer and expression in *E. coli* of the polypeptides represented by sequences SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively.

5 Figure 3 shows NS3 activity as a function of the concentration of glycerol.

Figure 4 shows NS3 activity as a function of the concentration of CHAPS, 3-[(3-colammide-propyl)-dimethyl-ammonium]-1-propanesulphonate.

10 Figure 5 shows NS3 activity as a function of pH.

Figure 6 shows NS3 activity as a function of ionic strength.

Figure 7 shows a diagram of the enzymatic assay to measure NS3 activity using as a substrate a peptide Ac-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Lys-ε-(3<sup>H</sup>)-Ac (SEQ ID NO:47).

Figure 8 shows the reaction diagram for synthesis of the depsipeptide substrate S1 represented by the sequence SEQ ID NO:42.

20 Figure 9 shows the reaction diagram for synthesis of the depsipeptide substrate S2 represented by the sequence SEQ ID NO:43.

Figure 10 shows the reaction diagram for synthesis of the radioactive depsipeptide substrate S1 represented by the sequence SEQ ID NO:44.

25 Figure 11 shows a high-throughput assay, based on radioactive signals, to determine NS3 protease activity.

Figure 12 shows the chemical formula of the depsipeptide substrates (SEQ ID NO:45 and SEQ ID NO:46) for a continuous assay of NS3 activity based on RET intramolecular fluorescence quenching.

Figure 13 shows the reaction diagram for synthesis of the depsipeptide substrate S3 (SEQ ID NO:45).

35 Figures 14A and 14B show, respectively, the kinetic parameters for the NS3 protease with the substrate S3 (SEQ ID NO:45) and fluorescence as a function of time in the relevant assay.

EXAMPLE 1Method of expression of HCV NS3 protease in *Spodoptera frugiperda* clone 9 cultured cells.

5 Systems for expression of foreign genes in insect cultured cells, such as *Spodoptera frugiperda* clone 9 (Sf9) cells infected with baculovirus vectors are known in the art (3). Heterologous genes are usually placed under the control of the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus or 10 the *Bombix mori* nuclear polyhedrosis virus. Methods for the introduction of heterologous DNA in the desired site in the baculoviral vectors by homologous recombination are also known in the art (4).

The plasmid vector pBacNS3 (1039-1226) is a 15 derivative of pBlueBacIII (Invitrogen) and was constructed for transfer of a gene coding for a polypeptide with the activity of NS3 (1039-1226). For this purpose, the nucleotide sequence coding for this polypeptide described in SEQ ID NO:1 was obtained by PCR 20 using oligonucleotides that insert an ATG codon at 5' and a TAG stop codon at 3' in the sequence. The fragment obtained in this way was inserted at the BamHI site of the vector pBlueBacIII, following treatment with the Klenow DNA polymerase fragment. The plasmid is 25 illustrated in figure 1.

*Spodoptera frugiperda* clone 9 (Sf9) cells and baculovirus recombination kits were purchased from 30 Invitrogen. Cells were grown on dishes or in suspension at 27°C in complete Grace's insect medium (Gibco) containing 10% foetal bovine serum (Gibco). Transfection, recombination, and selection of baculovirus constructs were performed as recommended by the manufacturer.

For protein expression, Sf9 cells were infected with 35 the recombinant baculovirus at a density of  $2 \times 10^6$  cells per ml in a ratio of about 5 virus particles per cell. The cells were cultivated in suspension for 72 hours at 23°C. Lowering the temperature from 27°C, which

corresponds normally to the optimal growth temperature, to 23°C is crucial in order to obtain a soluble and active protein.

After harvesting the cells by centrifugation and washing them with PBS (20 mM sodium phosphate pH 7.4, 140 mM NaCl) the pellet was re-suspended in 25 mM sodium phosphate pH 6.5, 20% glycerol, 0.5% 3-[(3-colammide-propyl)-dimethyl-ammonium]-1-propansulphonate (CHAPS), 10 mM dithiothreitol (DTT), 1 mM ethylenediamino-tetracetic acid (EDTA). The cells were destroyed at 4°C by means of four cycles of sonication at 10 W with a duration of 30 seconds each, using a Branson 250 instrument. The homogenate obtained in this way was pelleted by centrifugation at 120,000 x g for one hour and the supernatant was loaded onto an HR26/10 S-Sepharose column (Pharmacia) balanced with 25 mM sodium phosphate pH 6.5, 10% glycerol, 2 mM DTT, 1 mM EDTA, 0.1% CHAPS at a flow rate of 2 ml/min. After washing with two volumes of column the protease was eluted with an NaCl gradient between 0 and 1 M. The fractions containing the protease were identified using Western blotting methodology with NS3-specific polyclonal antibodies, concentrated to 3 ml using an Amicon ultrafiltration cell equipped with a Ym10 membrane and chromatographed onto a Superdex 75 HR26/60 column (Pharmacia) equilibrated with 50 mM sodium phosphate pH 7.5, 10% glycerol, 2 mM DTT, 0.1% CHAPS, 1 mM ESTA and a flow rate of 1 ml/min. The fractions containing the protease were pooled and underwent further chromatography on a Mono-S HR5/5 column (Pharmacia) equilibrated with the same buffer used in the previous column. The protease was eluted in a pure form from this column, applying a linear NaCl gradient between 0 and 0.5 M. The protease was stored at -80°C in 50% glycerol, 0.5% CHAPS, 10 mM DTT and 50 mM sodium phosphate pH 7.5. The yield of the process is 0.5 mg/l of cells. The purified protein has a catalytic activity  $K_{cat}/K_m=120-200 \text{ M}^{-1} \text{ s}^{-1}$  measured in 50 mM Tris pH 7.5, 50% glycerol, 2% CHAPS, 30

mM DTT at 23°C using the peptide substrate Fmoc-Tyr-Gln-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly (SEQ ID NO:7), derived from the polyprotein cleavage site between NS4A and NS4B. The cleavage products deriving from this reaction were separated using HPLC, isolated and identified by mass spectrometry, confirming that proteolytic cleavage took place between cysteine and alanine. The concentration of protease necessary to determine activity was between 100 nM and 1.6  $\mu$ M.

#### EXAMPLE 2

##### Method of expression of HCV NS3 protease in *E. coli*.

The plasmids pT7-7(NS3 1039-1226), pT7-7 (NS3 1039-1206), pT7-7 (NS3 1027-1206) and pT7-7 (NS3 1033-1206), described in figures 2A and 2B, were constructed in order to allow expression in *E. coli* of the polypeptides indicated in SEQ ID NO:2 and SEQ ID NO:3, and SEQ ID NO:4 and SEQ ID NO:5, respectively. The protein fragments contain variants of the protease domain of the HCV NS3 protein. The respective fragments of HCV cDNA were cloned downstream of the bacteriophage T7  $\phi$ 10 promoter and in frame with the first ATG codon of the phage T7 gene 10 protein, using methods that are known to the practice. The pT7-7 plasmids containing NS3 sequences also contains the gene for the  $\beta$ -lactamase enzyme that can be used as a marker of a selection of *E. coli* cells transformed with these plasmids.

The plasmids were then transformed in the *E. coli* strain BL21(DE53), which is normally employed for high-level expression of genes cloned into expression vectors containing the T7 promoter. In this strain of *E. coli*, the T7 polymerase gene is carried on the bacteriophage  $\lambda$  DE53, which is integrated into the chromosome of BL21 cells (5). Expression from the gene of interest is induced by addition of isopropylthiogalactoside (IPTG) to the growth medium according to a procedure that has been previously described (5). Over 90% of the proteins

expressed using one of the plasmids mentioned above is found in an insoluble form in inclusion bodies, from which it is possible to obtain a soluble and active protein following refolding methods known to the field (see for example (6)). Refolding protocols have often variable yields of catalytically active protein, and they require extremely controlled conditions, or cause irreversible modifications of the protein (such as carbamylation in the presence of urea), or require impractical procedures, such as the use of extremely diluted protein solutions, or dialysis of exceedingly large volumes of samples.

To avoid these problems, a method has been developed, which is described below, for the production of the HCV protease in a soluble and active form, avoiding thus resolubilisation protocols: *E. coli* BL21 (DE53) transformed using one of the plasmids mentioned above were grown at 37°C until reaching a cell density that causes absorption of 0.8 OD (OD stands for optical density) at 600 nm. At this point the temperature was lowered to 30°C in 15-20 minutes and 400 µM IPTG was added to induce expression of the protein. The temperature was then lowered further to 22-24°C within a period of 20-30 minutes. The cultures were stirred for a further 4 hours at this temperature. At this point the cells were harvested by centrifugation and washed using PBS.

#### Purification method

The pellets resulting from the operations described above were incubated on ice for 5 minutes and re-suspended in 25 mM sodium phosphate pH 6.5, 50% glycerol, 0.5% CHAPS, 10 mM DTT, 1 mM EDTA (buffer A) pre-cooled to 4°C. 10 ml of this buffer was used for each litre of bacterial culture. After a further 5-10 minutes of incubation on ice the cell suspension was homogenised using a French press. The resulting homogenate was

centrifuged at 120,000 x g. The supernatants from this centrifugation were preserved on ice, whereas the pellets were re-suspended in buffer A (1 ml to each litre of bacteria culture). After the addition of 1 mM MgCl<sub>2</sub> and DNaseI, the suspension was incubated for 10 minutes at 20°C and re-centrifuged for 1 hour at 120,000 x g. The supernatant from this second centrifugation was pooled with the first supernatant and the resulting protein solution was adsorbed on S-Sepharose (or SP-Sepharose) resin (Pharmacia) equilibrated with 25 mM sodium phosphate pH 6.5, 10% glycerol, 0.5% CHAPS, 3 mM DTT, 1 mM EDTA (buffer B). 10 ml of resin suspended in 5 ml of buffer B was used for each litre of bacterial culture. The resin was stirred for 1 hour at 4°C, collected by filtration, washed with buffer B and poured into an appropriate chromatography column. The protease was eluted with an NaCl gradient between 0 and 1 M. Fractions containing the protease were identified using Western blotting, pooled and concentrated using Centriprep 10 concentrators (Amicon) until reaching a concentration of 6-10 mg/ml in protein, determined using the BIORAD method. Up to 3 ml of this solution was loaded onto a HR 26/60 Superdex 75 or up to 20 ml was loaded onto an HR 60/600 Superdex 75 (both Pharmacia) equilibrated with 50 mM sodium phosphate pH 7.5, 10% glycerol, 3 mM DTT, 0.5% CHAPS (buffer C) and chromatography was carried out at 1 ml/min (HR26/60) or 5 ml/min (HR60/600). The fractions containing the protease were pooled and further purified by chromatography on HR 5/5 Mono S (Pharmacia) equilibrated with buffer C. The protease was eluted from this column with an NaCl gradient between 0 and 0.5 M. Purification to homogeneity was also possible with the following modification: after elution from S-Sepharose the fractions containing the protease were diluted 1:4 in buffer C and loaded onto Heparin-Sepharose. Elution from this resin was obtained with an NaCl gradient between 0 and 0.5 M. The protein was then chromatographed on



hydroxiapatite or Superdex 75 as described above. The yield is 1-2 mg of purified protein per litre of bacterial culture.

5        Characterisation of the purified protein

The purified protein was characterised by means of gel filtration, reverse-phase HPLC, mass spectrometry and N-terminal sequence analysis.

10        Analytical gel filtration experiments showed that the protein is monomeric. The protein expressed using pT7-7 (NS3 1027-1206) shows three peaks following reverse-phase HPLC chromatography. Mass spectrometry analysis and determination of the N-terminal sequence showed heterogeneity of the N-terminal portion of the molecule. Three forms were found, having the following N-terminal sequences:

15        Met-Ala-Pro-Ile-Thr-Ala-Tyr-Ser-Gln-Gln-Thr (form 1)

          Pro-Ile-Thr-Ala-Tyr-Ser-Gln-Gln-Thr (form 2)

                  Ser-Gln-Gln-Thr (form 3)

20        To avoid this problem, two experimental strategies were adopted:

1. Homogenisation in the presence of 100 µg/ml of the chymostatin protease inhibitor. This inhibitor does not inhibit HCV protease activity, but it does inhibit the  
25        chymotrypsin type proteases, specific for aromatic residues like phenylalanine and tyrosine. In this way it was possible to purify a single molecular species with more than 95% of form 2.

2. Production of a protease corresponding to form 3 by  
30        means of the plasmid pT7-7 (NS3 1033-1206). In this way a protein with more than 95% of form 3 was purified.

EXAMPLE 3

Method for reproducing in vitro the activity of the HCV NS3 protease

35        Definition of the chemical and physical conditions for reproduction of the activity.

The ability of the purified protease to catalyse cleavage of the peptide Fmoc-Tyr-Gln-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly (SEQ ID NO:7) has been used to define the optimum conditions for activity. Cleavage was detected by separating the substrate from the hydrolysis products by reverse-phase HPLC. For this purpose the mixture containing the buffer and the peptide incubated with the protease was injected into a reverse-phase Lichrospher RP-18 column (Merck) and eluted with an acetonitrile gradient containing 0.1% trifluoroacetic acid. The cleavage products were identified by co-injection of appropriate standards, and by mass spectrometry. For these experiments, proteins produced by one of the methods described in examples 1 and 2 were used.

Dependence of the activity on the glycerol concentration was determined in a buffer containing 50 mM Tris pH 7.5, 2% CHAPS, 30 mM DTT. Increasing concentrations of glycerol were added to this buffer, and the relative protease activity was determined. Figure 3 shows the results of this experiment, indicating that 50% (v/v) glycerol is the optimum level. In a subsequent experiment this concentration was kept constant at 50% and the concentration of CHAPS was varied (figure 4). A level of 2% CHAPS (w/v) was in this way found to be the optimum concentration. It was possible to replace CHAPS with other detergents compatible with the need to maintain catalytic activity in the polypeptides according to the invention. Some of these detergents are: heptyl- $\beta$ -D-glucopyranoside, decyl- $\beta$ -D-glucopyranoside, decyl- $\beta$ -D-glucomaltoside, nonyl- $\beta$ -D-glucopyranoside, N-hexyl- $\beta$ -D-glucopyranoside, octyl- $\beta$ -D-glucopyranoside, octyl- $\beta$ -D-thio-glucopyranoside, Nonidet P-40, Tween-20.

At optimum CHAPS and glycerol concentrations the protease shows optimal activity at pH 8.5 (figure 5). At this pH the stability over time is, however, lower than that seen at pH 7.5. To determine the effect of ionic

strength on the activity, a titration was performed using NaCl. This experiment showed that protease activity is inhibited at a high ionic strength (figure 9). Kinetic analysis of data showed that chloride ions are competitive inhibitors at concentrations of up to 100 mM.

It was thus possible to define the following optimal conditions for in vitro assay of purified HCV protease activity: 50 mM Tris pH 7.5, 3-30 mM DTT, 2% CHAPS, 50% glycerol. Dependence of the activity on temperature was analysed by means of an Arrhenius plot in which the logarithm of the kinetic constant  $K_{cat}$  is given as an inverse function of temperature. This graph shows discontinuity at temperatures above 25°C, indicating changes in conformation simultaneously to the decrease in activity. The optimum temperature was thus determined to be around 22-23°C.

As mentioned above, the protein NS4A is a cofactor of HCV protease. N and C-terminal deletion experiments have defined the peptide Pep4A with the sequence indicated in SEQ ID NO:6, as the minimum domain still capable of inducing optimal activation. In transfection or in vitro translation experiments the addition of polypeptides containing the minimum NS4A sequence is essential to give effective cleavage. The addition of Pep4A is capable of inducing a significant increase in the activity of purified protease in the assay conditions described above. The kinetic characteristics of this activation are described below. Using a titration experiment a stoichiometry of 1:1 was determined for this interaction at a concentration of 300 nM of protease, indicating a  $K_d < 300$  nM.

#### Definition of the optimal substrate for activity assay

To define the minimum substrate whose cleavage can still be detected using the HPLC method described above, derivatives of the peptide Fmoc-Tyr-Gln-Glu-Phe-Asp-Glu-

Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly  
 (SEQ ID NO:7) described above were synthesized, with N-  
 and/or C-terminal deletions. These peptides were  
 incubated in the conditions defined in the preceding  
 chapter in the presence of 100 nM-1.6  $\mu$ M protease. The  
 nomenclature for the amino acid residues of the peptides  
 used as substrates that is adopted in the following is  
 that set down by Schechter and Berger in (7). The  
 residues are defined as Pn....P3, P2, P1, P1', P2',  
 P3'....Pn', where the hydrolysed bond is P1-P1' (bond  
 between Cys and Ala). Table 1 shows the kinetic data for  
 this experiment, defining P6 and P3' or P4' as the  
 extreme limits of a substrate that is still effectively  
 cleaved. Deletions beyond P6 or P3' cause a drastic  
 decrease in effectiveness, measured as  $k_{cat}/K_m$ , with which  
 the respective peptide can still act as a substrate.  
 Deletion of P4' causes a less marked decrease of  $k_{cat}/K_m$ ,  
 however the separation of substrate and cleavage product  
 by HPLC is significantly better for a decapeptide P6-P4'  
 than for a nonapeptide P6-P3', so that the decapeptide  
 P6-P4' has been defined the optimal substrate.

Table 1: Characterisation of substrate

Peptide	$K_m$ ( $\mu$ M)	$k_{cat}$ ( $\text{min}^{-1}$ )	$k_{cat}/K_m$ ( $\text{M}^{-1}\text{s}^{-1}$ )
(SEQ ID NO: 7) Fmoc-YQEFDEMEECASHLPYIEQG	53	0.5	143.0
(SEQ ID NO: 8) Ac-YQEFDEMEECASHLPY	56	0.3	87.0
(SEQ ID NO: 9) Ac-YQEFDEMEECASHLP	95	0.4	70.2
(SEQ ID NO:10) Ac-YQEFDEMEECASHL	117	0.4	51.0
(SEQ ID NO:11) Ac-YQEFDEMEECASH	197	0.3	24.0
(SEQ ID NO:12) Ac-YQEFDEMEECAS	>1500	-	11.1
(SEQ ID NO:13) Ac-YQEFDEMEECA		no cleavage	
(SEQ ID NO:14) Ac-DEMEECASHLPY	171	0.3	34.0
(SEQ ID NO:15) Ac-EMEECASHLP	3137	0.3	2.0
(SEQ ID NO:16) Ac-MEECASHL		no cleavage	
(SEQ ID NO:17) Ac-ECASHLPYIEQG		no cleavage	
(SEQ ID NO:18) Ac-DEMEECASHL	100	0.3	47

(SEQ ID NO:19) DEMEEECASHL	85	0.1	22.7
(SEQ ID NO:20) Fmoc-DEMEEECASHL	95	0.1	23.8

The kinetic parameters  $K_m$ ,  $k_{cat}$  and  $k_{cat}/K_m$  were determined for decapeptides P6-P4' corresponding to the other two intermolecular cleavage sites NS4B/5A and NS5A/5B and this data was compared with the data obtained using the peptide P6-P4' corresponding to the site NS4A/4B (table 2). These kinetics were obtained both in the absence and in the presence of stoichiometric concentrations of Pep4A. Analysis of the kinetic data obtained in this fashion indicates that Pep4A prevalently affects  $k_{cat}$ . When the  $K_m$  values for the single substrates are compared it becomes evident that the presence of two negative charges in P5 and in P6 determined the bonding effectiveness of a peptide substrate. In fact decapeptides corresponding to the sites NS4A/4B and NS5A/5B with Asp or Glu residues in position P6 and P5 have  $K_m$  values similar and significantly lower than the peptide corresponding to site NS4B/5A with a single charge in position P6.

TABLE 2: Activity on peptides corresponding to cleavage sites in trans

Peptide	$K_m$ ( $\mu M$ )	$k_{cat}$ ( $min^{-1}$ )	$k_{cat}/K_m$ ( $M^{-1}s^{-1}$ )
NS4A/4B			
(SEQ ID NO:18) Ac-DEMEEECASHL	100	0.3	47.0
(SEQ ID NO: 6) + <i>pep4A</i>	43	1.4	540
NS4B/5A			
(SEQ ID NO:21) Ac-DCSTPCSGSW	2100	0.05	0.4
(SEQ ID NO: 6) + <i>pep4A</i>	320	0.8	4.2
NS5A/NS5B			
(SEQ ID NO:22) Ac-EDVVCCSMSY	310	4.2	220
(SEQ ID NO: 6) + <i>pep4A</i>	380	15	650

Further investigation was carried out on the relative importance of single residues within the sequence P6-P4', corresponding to the cleavage site NS4A/4B, by mutating each amino acid singly to alanine and then determining the kinetic parameters for the mutant peptides obtained in this way. The results are described in table 3. This experiment identifies the following scale of importance of single residues for effective cleavage: P1>>P3=P5=P6>P2=P4. Modification of the P' part does not have a significant effect on the rate of cleavage. This information was used to develop protease activity assay methods, useful for the identification of inhibitors. These methods will be described below.

TABLE 3. Replacement with alanine of residues P6-P4' of the peptide substrate

Peptide	$K_m$ ( $\mu M$ )	$k_{cat}$ ( $min^{-1}$ )	$k_{cat}/K_m$ ( $M^{-1}s^{-1}$ )
(SEQ ID NO:18) Ac-DEMEECASHL	100	0.3	47.0
(SEQ ID NO:23) Ac-AEMEECASHL	150	0.1	9.4
(SEQ ID NO:24) Ac-DAMEECASHL	527	0.3	9.3
(SEQ ID NO:25) Ac-DEAEECASHL	114	0.1	18.1
(SEQ ID NO:26) Ac-DEMAECASHL	322	0.1	7.2
(SEQ ID NO:27) Ac-DEMEACASHL	132	0.1	18.4
(SEQ ID NO:28) Ac-DEMEEAASHL		no cleavage	
(SEQ ID NO:29) Ac-DEMEECAAHL	129	0.2	32.5
(SEQ ID NO:30) Ac-DEMEECASAL	180	0.3	33.4
(SEQ ID NO:31) Ac-DEMEECASHA	94	0.1	23.2

For more detailed determination of the importance of the residues in P6 and P1', a series of peptides P6-P4' were synthesised in which modifications were introduced in these positions. The results of these experiments are described in table 4. The results of these experiments underline the importance of a negative charge in position P6. In fact, Asp or Glu in this position are accepted with indistinguishable  $K_m$ . Neutralisation of the charge

by introduction of Asn causes a significant increase in  $K_m$ , whereas inversion of the charge by introduction of a Lys residue causes an extremely marked increase in  $K_m$ .

5 TABLE 4. Substitution of residues P6 and P1' in the peptide substrate

Peptide	$K_m$ ( $\mu M$ )	$k_{cat}$ ( $min^{-1}$ )	$k_{cat}/K_m$ ( $M^{-1}s^{-1}$ )
(SEQ ID NO:18) Ac-DEMEECASHL	100	0.3	47.0
(SEQ ID NO:32) Ac-EEMEECASHL	85	0.2	32.0
(SEQ ID NO:33) Ac-NEMEECASHL	427	0.2	7.7
(SEQ ID NO:34) Ac-KEMEECASHL	>1000	-	3.1
(SEQ ID NO:35) Ac-DEMEECSSHL			27.2
(SEQ ID NO:36) Ac-DEMEECFSHL			1.1

Substitution of Ala in position P1' with Ser has no significant effect, whereas substitution with Phe causes a reduction in the cleavage rate of the resulting substrate, measured as  $k_{cat}/K_m$ .

10 Analysis was carried out on a series of mutations of the position P1, described in table 5. Substitution of cysteine in this position with threonine, alylglycine,  $\alpha$ -aminobutyric acid, norvaline and valine are accepted, even though the resulting substrates are cleaved with an efficiency, expressed as  $k_{cat}/K_m$ , which is significantly lower than that of the unmodified substrate.

15 TABLE 5. Substitution of the peptide substrate residue P1

Peptide substrate	$k_{cat}/K_m$ ( $M^{-1}s^{-1}$ )
(SEQ ID NO:18) Ac-DEMEECASHL	47.0
(SEQ ID NO:37) Ac-DEMEEAlgASHL	4.3
(SEQ ID NO:38) Ac-DEMEEAbuASHL	1.2
(SEQ ID NO:39) Ac-DEMEETASHL	0.6
(SEQ ID NO:40) Ac-DEMEENvvaASHL	0.08
(SEQ ID NO:41) Ac-DEMEEVASHL	0.05

Alg, alylglycine; Abu,  $\alpha$ -aminobutyrric acid; Nva, norvaline

The information relating to substrate specificity can be used both for development of enzyme assays and for synthesis of inhibitors based on modified substrate sequences. For example, substrate peptides with modified P1 residues are competitive inhibitors of protease with inhibition constants  $K_i$  of between 350 and 90  $\mu\text{M}$  (table 6). These peptides can be further modified to increase their inhibitory power by introduction of aldehyde, trifluoromethylketone, difluoromethylenketone, diketone, ketoester, ketoamide or  $\alpha$ -ketoheterocyclic, boronic acid and monoalomethylketone groups. Information on specificity can also allow synthesis of inhibitors that are not based on peptides, such as: halo-enolactones, isocoumarines,  $\beta$ -lactames, succinimides, pyrones, bezoxyazynones, bezoiso-thiazolines or latent isocyanates.

TABLE 6. Inhibitory action of decapeptides P6-P4' modified at position P1

residue P1	$K_i$ ( $\mu\text{M}$ )	$K_m$ ( $\mu\text{M}$ )
Cys	-	90
Abu	175	189
Alg	165	179
Thr	215	180
Val	173	not determined
Ala	173	no cleavage
Ser	90	no cleavage
Gly	191	no cleavage
Pro	440	no cleavage
Cha	350	no cleavage

Abu,  $\alpha$ -aminobutyric acid; Alg, alylglycine; Cha, ciclohexylalanin.

#### EXAMPLE 4

#### Method for using in vitro protease activity for inhibitor research

Automatic assay using an amide substrate



The peptide Ac-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Lys- $\epsilon$ -( $^3\text{H}$ )Ac, (SEQ ID NO:47) derived from the cleavage site NS4A/NS4B, is cleaved by the NS3 protease with the following kinetic parameters:  $K_m = 79 \mu\text{M}$ ,  $k_{\text{cat}} = 0.49 \text{ min}^{-1}$  and  $k_{\text{cat}}/K_m = 103 \text{ M}^{-1} \text{ s}^{-1}$ . 400,000 cpm of the labelled peptide with a specific activity of 2-10 Ci/mmol. were incubated for 3 hours at 23°C together with 40  $\mu\text{M}$  ( $K_m/2$ ) of unlabeled peptide in the presence of 200 nM protease and 1  $\mu\text{M}$  of Pep4A in 50 mM Tris pH 7.5, 50% glycerol, 3% CHAPS, 10 mM DTT. During this period 20% of the peptide substrate was cleaved. The cleavage product can be quantified following the method described below and summarised in figure 7. As can be seen from the figure, the mixture is placed in contact with a TSK-DEAE anionic exchanger. The fraction coming out of the exchanger is filtered, allowed to sediment or spun. The radioactivity is measured on the clear fraction, the amount of which is exclusively related to the right fragment (C-terminal), given that the amide substrate and the left hand fragment remain bound to the anionic exchanger. The addition of inhibitors causes a decrease in the release rate of the labelled cleaved fragment. The more effective the inhibitor, the lower will be the radioactivity measured in the fraction coming out of the anionic exchanger.

#### EXAMPLE 5

##### Synthesis of the depsipeptide substrate S1:

Ac-Asp-Glu-Met-Glu-Glu-Abu-w[COO]-Ala-Ser-His-Leu-Pro-Tyr-Lys(N $^{\epsilon}$ -Ac)-NH $_2$  (SEQ ID NO:8)

The synthesis was performed entirely on solid-phase using the continuous-flow Fmoc-polyamide method (9). The protecting group combination was: base-labile N $\alpha$ -Fmoc for the  $\alpha$ -amino group and acid-labile protection for the side-chains: Asp(Ot-Bu), Glu(Ot-Bu), Tyr(t-Bu) and His(trt). The polymer used was composite Kieselguhr-polyamide (9) derivatised with a modified Rink amide linker (10), p-[(R,S)-a-[1-(9H-Fluoren-9-yl)-

methoxyformamido]-2,4-dimethoxybenzyl]-phenoxyacetic acid (11) (NovaSyn ® KR 125, 0.1 mmol/g). The resin, amino acid derivatives, activating agents and all other reagents were of the highest available grade from commercial sources. The synthesis was run according to the scheme given in figure 8. Couplings were performed with 5-fold excess of activated amino acid over the resin free amino groups, using Fmoc-amino acid/PyBOP/HOBt/DIEA (1:1:1:2) activation, except for L-(+)-lactic acid where Fmoc-amino acid/DIPC/HOBt (1:1:1:1) activation was used. Esterification of Abu to the free hydroxyl of lactic acid was performed using the symmetrical anhydride (Fmoc-Abu)<sub>2</sub>O in the presence of a catalytic amount (0.1 equiv.) of DMAP, for 30 minutes at room temperature (12): the reaction was repeated twice to achieve 90% yield; in the absence of catalyst, the remaining free hydroxyls are unreactive in subsequent synthetic operations. At the end of the assembly, the resin was washed with DMF, methanol and CH<sub>2</sub>Cl<sub>2</sub>, then dried in vacuo for 16 hours. The dry peptide-resin was treated with TFA/water/triisopropylsilane (92.5:5:2.5) for 1.5 hours at room temperature; the resin was filtered out and the peptide precipitated with cold methyl t-Bu ether; the precipitate was redissolved in 50% water/acetonitrile containing 0.1% TFA and lyophilised.

Purification to >98% homogeneity was achieved through preparative HPLC on a Nucleosyl C-18 column (250x21 mm, 7 µM) using as eluents (A) water and (B) acetonitrile with 0.1% TFA, and a step gradient 22%B over 5 minutes, then 22-27%B over 25 minutes, flow rate 12 ml/min. In these conditions the peptide elutes at 21.9 minutes. The fractions containing the pure material were pooled and lyophilised: yield 35%.

#### EXAMPLE 6

Chemical synthesis of the depsi-peptide substrate S2:  
Ac-Asp-Glu-Met-Glu-Glu-Thr-ψ-[COO]-Ala-Ser-His-Leu-Pro-  
Tyr-Lys(N<sup>t</sup>-Ac)-NH<sub>2</sub> (SEQ ID NO:43)

The synthesis was performed as described in the previous example. Esterification of Thr to lactic acid required three repetitions to obtain a 70% yield, which was also accompanied by 3% racemization of the Thr residue. The D-Thr diastereoisomer was however chromatographically well resolved from the L-isomer, and easily resolved by preparative HPLC. The gradient used was 21%B over 5 minutes, then 21-22%B over 20 minutes, with the desired peptide eluting at 19.7 minutes: yield 24%.

#### EXAMPLE 7

Synthesis of the radioactive depsipeptide substrate S1:  
Ac-Asp-Glu-Met-Glu-Glu-Abu-ψ-[COO]-Ala-Ser-His-Leu-Pro-  
Tyr-Lys(N<sup>f</sup>-[<sup>3</sup>H]-CH<sub>2</sub>CO)-NH<sub>2</sub> (SEQ ID NO:44)

To selectively label peptide S1 on the N<sup>f</sup>-amino group of the C-terminal lysine, the protected precursor Ac-Asp(Ot-Bu)-Glu(Ot-Bu)-Met-Glu(Ot-Bu)-Glu(Ot-Bu)-Abu-ψ[COO]-Ala-Ser(t-Bu)-His(Trt)-Leu-Pro-Tyr(t-Bu)-Lys-CONH<sub>2</sub> was assembled on the resin according to the scheme of figure 10. The only variation with respect to the synthesis of (N<sup>f</sup>-Ac)-S1 was the use of Fmoc-Lys(Alloc)-OH instead of Fmoc-Lys(N<sup>f</sup>-Ac)-OH. The Alloc protection is orthogonal with respect to Fmoc and t-Bu based protecting groups, being removed with a two hour treatment with (0) PdP[(Ph<sub>3</sub>)<sub>4</sub>] in a solution of CHCl<sub>3</sub>, containing 5% acetic acid and 2.5% N-methylmorpholine.

The dry peptide-resin (0.07 mmol/g, 60 mg) was reacted with [<sup>3</sup>H] acetic anhydride (25 mCi, 5.7 mCi/mmol) for 16 hours at room temperature. A 10-fold excess of non-radioactive acetic anhydride was then used to complete the reaction. The resin was then washed with DMF and treated as previously described. After preparative HPLC, >98% pure peptide Ac-Asp-Glu-Met-Glu-Glu-Abu-ψ-[COO]-Ala-Ser-His-Leu-Pro-Tyr-Lys(N<sup>f</sup>-[<sup>3</sup>H]-CH<sub>2</sub>CO)-NH<sub>2</sub> was obtained with a specific activity of 0.68 mCi/mmol.

Using the HPLC-based assay, the following kinetic parameters were obtained for the radioactive depsipeptide substrate S1 (SEQ ID NO:44):

$$K_{cat}(\text{min}^{-1}) = 9$$

5  $K_m(\mu\text{M}) = 11$

$$K_{cat}/K_m(\text{M}^{-1}\text{s}^{-1}) = 13.636$$

Using the same assay, the kinetic parameters for the radioactive substrate S2 are

$$K_{cat}(\text{min}^{-1}) = 16$$

10  $K_m(\mu\text{M}) = 96$

$$K_{cat}/K_m(\text{M}^{-1}\text{s}^{-1}) = 2.780.$$

Synthesis of the radioactive depsipeptide substrates allows set-up of a high-throughput assay for determination of NS3 protease activity as schematically illustrated in figure 11. The principle is the following: both the intact substrate and the N-terminal fragment that originates from enzyme cleavage (Ac-Asp-Glu-Met-Glu-Glu-Abu-OH) are extremely acid, whereas the C-terminal fragment [HO-CH(CH<sub>3</sub>)CO-Ser-His-Leu-Pro-Tyr-Lys(N<sup>ε</sup>-[<sup>3</sup>H]-CH<sub>3</sub>CO)-NH<sub>2</sub>] is, according to pH, neutral or basic. It is therefore possible to capture the two acidic species on an anionic exchange resin, leaving the C-terminal fragment in solution. If the C-terminal fragment contains a radioactive marker (in this case the tritiated acetate covalently bonded to the ε-amino group of the C-terminal lysine), the resin will be able to discriminate processed substrate from non-processed substrate, thus making it possible to quantify proteolytic activity by measuring the amount of radioactivity remaining in solution after incubation with the enzyme and treatment with the ion exchanger. The whole process is essentially the same used in the high-throughput assay based on the amide substrate of example 4, but the pH used in this case is 7.0 instead of 7.5 to minimise spontaneous hydrolysis of the ester bond (0.6%/hour at 23°C).

15  
20  
25  
30  
35

#### EXAMPLE 8

Synthesis of the depsipeptide substrates S3 and S4:

Ac-Asp-Glu-Asp-(EDANS)-Glu-Glu-Abu- $\psi$ [COO]-Ala-Ser-Lys-(DABCYL)NH<sub>2</sub> (SEQ ID NO:45) and Ac-Asp-Asp-(EDANS)-Met-Glu-Glu-Abu- $\psi$ [COO]-Ala-Ser-Lys(DABCYL)NH<sub>2</sub> (SEQ ID NO:46)

The chemical formula of the two substrates S3 and S4 is shown in figure 11.

The synthesis was performed on solid phase as detailed in the scheme of figure 13 for S3 (SEQ ID NO:45), making use of two special derivatives, Fmoc-Asp(EDANS)-OH and Fmoc-Lys(DABCYL)-OH, prepared according to known methods (16-17). All the couplings, including Asp(EDANS) and Lys(DABCYL), were performed with 5-fold excess of activated amino acid over the resin free amino groups, using Fmoc-amino acid/PyBOP/HOBt/DIEA (1:1:1:2) activation, with the exception of L-(+)-lactic acid where Fmoc-amino acid/DIPC/HOBt (1:1:1.1) activation was used. Esterification of Abu to the free hydroxyl of lactic acid was performed using the symmetrical anhydride (Fmoc-Abu)<sub>2</sub>O in the presence of a catalytic amount (0-1 equiv.) of DMAP, for 30 minutes at room temperature (12): the reaction was repeated twice to achieve 92% yield. At the end of the assembly, the peptide-resin was washed and the peptide cleaved as described for substrate S1.

Purification to >98% homogeneity was achieved through preparative HPLC on a Nucleosyl C-18 column (250x21 mm, 7 $\mu$ m) using as eluents (A) 50 mM ammonium acetate, pH 6 and (B) acetonitrile. The gradient used for both S3 and S4 was 20%B over 5 minutes, then 20-40%B over 20 minutes, flow rate 20 ml/min; the fractions containing the pure material were pooled and lyophilised: yield 45% and 35% for S3 and S4, respectively. The kinetic parameters for this substrate, evaluated through the HPLC-based assay (see figure 14A), were the following:

$$K_{cat}(\text{min}^{-1}) = 3.51$$

$$K_m(\mu\text{M}) = 10.95$$

$$K_{cat}/K_m(\text{M}^{-1}\text{s}^{-1}) = 5342.$$

The buffer used for the assay is the following: 33 mM DTT, 50 mM Tris, pH 7, 50% glycerol, 2% CHAPS. The

incubation is carried out at pH 7.0 to minimise spontaneous hydrolysis of the ester bond. The assay can be run in a cuvette or in a (96-well) microtitre plate, monitoring the fluorescence as a function of time (Excitation wavelength 355 nM, Emission wavelength 495 nM). The increase in fluorescence upon substrate cleavage is 13-fold. The reaction is linear as shown in figure 14B (fixed substrate concentration = 2  $\mu$ M). The detection limit was established as 1 nM for the high-throughput microplate assay and 520 pM for the HPLC-based assay. If a continuous (cuvette) assay is performed to establish initial rates for the enzymatic reaction, the lower limit for enzyme concentration is 80 nM, because of fluorescence quenching of the cleaved substrate at substrate concentrations higher than 10  $\mu$ M.

#### DEPOSITS

Strains of *E. coli* DH1 - transformed using the plasmids pBac (1039-1226), pT7-7 (1039-1226), pT7-7 (1039-1206), pT7-7 (1027-1206) and pT7-7 (1033-1206) coding, respectively, for the polypeptides with amino acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 - were deposited on 14 August 1995 with The National Collections of Industrial and Marine Bacteria Ltd. (NCIMB), Aberdeen, Scotland, U.K., with access numbers NCIMB 40761, NCIMB 40762, NCIMB 40763, NCIMB 40764 and NCIMB 40765.

REFERENCES

1. Chambers, T. J: et al 1990, Evidence that the N-terminal domain of non structural protein NS3 from yellow fever virus is serine protease responsible for site specific cleavages in the viral polyprotein, Proc. Natl. Acad. Sci. USA 87, 8898-8902.
2. Lam, P.Y. S. et al, 1994, Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors, Science 263, 380-384.
3. Luckow, V.A., Baculovirus systems for the expression of human gene products, (1993) Current Opinion in Biotechnology 4, 564-572.
4. O'Reilly, D.R., Miller, L.K., Luckow, V.A., (1992), Baculovirus Expression Vectors - A Laboratory Manual, W.H. Freeman and Company, New York.
5. Studier and Moffatt, Use of Bacteriophage T7 RNA polymerase to direct selective high level expression of cloned genes, (1986), J. Mol. Biol. 189, 113-130.
6. Thatcher and Hitchcock, Protein folding in Biotechnology, in: Mechanism of protein folding (edited by R.H. Pain), 226-263, IRL Press Oxford, New York, Tokyo, (1994).
7. Schechter and Berger, 1968, On the size of the active site in proteases I papain, Biochem. Biophys. Res. Commun. 27, 127-162.
8. Fersht, A. (1985) Enzyme structure and mechanism, W.H. Freeman, New York.
9. Atherton, E., Brown, E., Sheppard, R.C. and Rosevear, A. (1981) J. Chem. Soc., Chem. Commun., 1151.
10. Rink, H. (1987) Tetrahedron Lett. 28, 3782.
11. Bernatowicz, M.S., Daniels, S.B. and Koster, H. (1989) Tetrahedron Lett. 30, 4645.
12. Atherton, E. and Sheppard, R.C. (1989) Solid phase peptide synthesis, a practical approach, IRL Press, Oxford.
13. Matayoshi, E.D., Wang, G.T., Krafft, G.A., and Erickson, J., (1990) Science 247, 954.

14. Maggiora, L.L., Smith, C.W. and Zhang, Z.Y. (1992) J. Med. Chem. 35, 3727.
15. Wang, G.T., Chung, G.C., Holzman, T.F. and Kraft, G.A. (1993) Anal. Biochem. 210, 351-359.
- 5 16. Andreae, F., Sommergruber, W., Gauss-Muller, V., Schultheis, T. and Ahorn, H. (1994) Innovations and Perspectives in solid Phase Synthesis, R. Epton, ed., Mayflower Worldwide Ltd., Birmingham, UK, pp. 433-436.
17. Kraft, G.A. and Wang, G.T. (1994) Methods  
10 Enzymol. 241, 70.
18. Pennington, M.W. and Thornberry, N.A. (1994) Peptide Res. 7, 72.
19. Holskin, B.P., Bukhtiyarova, M., Dunn, B.M., Baur, P., J. de Chastonay and Pennington, M.W. (1995)  
15 Anal. Biochem. 226, 148.

ABBREVIATIONS AND SYMBOLS USED IN THE TEXT

- Abu = 2-aminobutyric acid; CHAPS = 3-[(3-colammide-propyl)-dimethyl-ammonium]-1-propansulphonate; DABCYL =  
4-[[4'-(dimethylaminophenyl)azo]benzoic acid;
- 20 Depsipeptide = a peptide where at least one peptide bond is replaced by the corresponding ester bond (the location(s) of the ester bond(s) within the molecule is usually indicated as  $\psi$ [COO]- between the amino acid residues involved); DIEA = N,N-diisopropylethylamine;
- 25 DIPC = N,N'-diisopropylcarbodiimide; DMAP = 4-dimethylaminopyridine; DMF = N,N-dimethylformamide; DTT = dithiothreitol; EDANS = 5-[(2'-aminoethyl)amino]naphthalenesulfonic acid; EDTA = ethylenediamino-tetracetic acid; HOBt = N-hydroxybenzotriazole;
- 30 HPLC = high-performance liquid chromatography; PyBOP = Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate; RET = resonance energy transfer; t-Bu = tertiary-butyl; TFA = trifluoroacetic acid; Trt (Trityl) = triphenylmethyl.



## SEQUENCE LISTING

## GENERAL INFORMATION

- (i) APPLICANT: ISTITUTO DI RICERCHE DI BIOLOGIA  
MOLECOLARE P. ANGELETTI S.p.A.
- 5 (ii) TITLE OF INVENTION: METHODOLOGY TO PRODUCE,  
PURIFY AND ASSAY POLYPEPTIDES WITH THE  
PROTEOLITIC ACTIVITY OF THE HCV NS3 PROTEASE
- (iii) NUMBER OF SEQUENCES: 47
- (iv) CORRESPONDENCE ADDRESS:
- 10 (A) ADDRESSEE: Societa Italiana Brevetti  
(B) STREET: Piazza di Pietra, 39  
(C) CITY: Rome  
(D) COUNTRY: Italy  
(E) POSTAL CODE: 1-00186
- 15 (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk 3.5" 1.44  
MBYTES  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS Rev.6.22  
20 (D) SOFTWARE: Microsoft Word 6.0
- (viii) ATTORNEY INFORMATION  
(A) NAME: DI CERBO, Mario (Dr.)  
(C) REFERENCE: RM/X88568/PC-DC
- (ix) TELECOMMUNICATION INFORMATION
- 25 (A) TELEPHONE: 06/6785941  
(B) TELEFAX: 06/6794692  
(C) TELEX: 612287 ROPAT
- (1) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS
- 30 (A) LENGTH: 191 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:
- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys  
1 5 10 15

Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser  
                   20                                  25                                  30  
 Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly  
                   35                                  40                                  45  
 5 Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met  
                   50                                  55                                  60  
 Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly  
                   65                                  70                                  75                                  80  
 Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu  
 10                                  85                                  90                                  95  
 Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser  
                   100                                  105                                  110  
 Arg Gly Ser Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser  
                   115                                  120                                  125  
 15 Ser Gly Gly Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe  
                   130                                  135                                  140  
 Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val  
                   145                                  150                                  155                                  160  
 Pro Val Glu Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp  
 20                                  165                                  170                                  175  
 Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala Leu  
                   180                                  185                                  190

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS

- 25 (A) LENGTH: 195 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ix) FEATURE:

- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Arg Ile Arg Ala Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr  
 1                                  5                                  10                                  15  
 Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr  
                   20                                  25                                  30  
 35 Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr  
                   35                                  40                                  45  
 Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro

50 55 60  
 Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln  
 65 70 75 80  
 Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser  
 5 85 90 95  
 Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg  
 100 105 110  
 Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Val Ser Tyr  
 115 120 125  
 10 Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ser Gly His Ala  
 130 135 140  
 Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala  
 145 150 155 160  
 Val Asp Phe Val Pro Val Glu Ser Met Glu Thr Thr Met Arg Ser Pro  
 15 165 170 175  
 Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln  
 180 185 190  
 Val Ala Leu  
 195

20 (3) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ix) FEATURE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met Ala Arg Ile Arg Ala Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr  
 1 5 10 15  
 30 Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr  
 20 25 30  
 Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr  
 35 40 45  
 Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro  
 35 50 55 60  
 Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln  
 65 70 75 80

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met	Ala	Pro	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu	Leu	Gly
1				5					10					15	
Cys	Ile	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val	Glu	Gly
			20					25					30		
Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala	Thr	Cys
			35				40						45		
Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser	Lys	Thr
	50					55					60				
Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn	Val	Asp
65					70					75					80
Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser	Leu	Thr
				85					90					95	
Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg	His	Ala
			100						105					110	
Asp	Val	Ile	Pro	Val	Arg	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	Leu	Leu
		115					120					125			
Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ser	Gly	Gly	Pro	Leu

130                      135                      140  
 Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys  
 145                      150                      155                      160  
 Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met  
 5                      165                      170                      175  
 Glu Thr Thr Met Arg  
 180

## (5) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

## (ix) FEATURE:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr  
 1                      5                      10                      15  
 Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr  
 20                      25                      30  
 Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr  
 35                      40                      45  
 Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro  
 50                      55                      60  
 Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln  
 25                      65                      70                      75                      80  
 Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser  
 85                      90                      95  
 Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg  
 100                      105                      110  
 Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Val Ser Tyr  
 30                      115                      120                      125  
 Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ser Gly His Ala  
 130                      135                      140  
 Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala  
 35                      145                      150                      155                      160  
 Val Asp Phe Val Pro Val Glu Ser Met Glu Thr Thr Met Arg  
 165                      170

## (6) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ix) FEATURE:

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

10    Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu Ser Gly Arg  
      1                    5                    10

## (7) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Fmoc-Tyr

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

25    Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala Ser His Leu Pro Tyr  
      1                    5                    10                    15  
      Ile Glu Gln Gly  
                          20

## (8) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Tyr

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

35    Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala Ser His Leu Pro Tyr

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(D) FURTHER INFORMATION: Xaa is Ac-Tyr

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala Ser His Leu Pro

15 (10) INFORMATION FOR SEQ ID NO: 10:

(D) TOPOLOGY: linear

(D) FURTHER INFORMATION: Xaa is Ac-Tyr

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10;

Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala Ser His Leu

(11) INFORMATION FOR SEQ ID NO: 11:

(D) TOPOLOGY: linear

(D) FURTHER INFORMATION: Xaa is Ac-Tyr

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:  
Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala Ser His  
1 5 10
- (12) INFORMATION FOR SEQ ID NO: 12:
- 5 (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- 10 (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Tyr
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
- 15 Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala Ser  
1 5 10
- (13) INFORMATION FOR SEQ ID NO: 13:
- 20 (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide  
25 (B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Tyr
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
- Xaa Gln Glu Phe Asp Glu Met Glu Glu Cys Ala  
1 5 10
- 30 (14) INFORMATION FOR SEQ ID NO: 14:
- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
35 (D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide



(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Asp

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Xaa Glu Met Glu Glu Cys Ala Ser His Leu Pro Tyr

5      1                                  5                                  10

(15) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

10      (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

15      (D) FURTHER INFORMATION: Xaa is Ac-Glu

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Xaa Met Glu Glu Cys Ala Ser His Leu Pro

1                                  5                                  10

(16) INFORMATION FOR SEQ ID NO: 16:

20      (i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25      (ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Met

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

30      Xaa Glu Glu Cys Ala Ser His Leu

1                                  5

(17) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

35      (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

- (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Glu
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:  
Xaa Cys Ala Ser His Leu Pro Tyr Ile Glu Gln Gly  
1 5 10
- (18) INFORMATION FOR SEQ ID NO: 18:  
(i) SEQUENCE CHARACTERISTICS  
10 (A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
15 (A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:  
Xaa Glu Met Glu Glu Cys Ala Ser His Leu  
20 1 5 10
- (19) INFORMATION FOR SEQ ID NO: 19:  
(i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
25 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION:  
30 (D) FURTHER INFORMATION:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:  
Asp Glu Met Glu Glu Cys Ala Ser His Leu  
1 5 10
- (20) INFORMATION FOR SEQ ID NO: 20:  
35 (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid

- 41 -

(C)STRANDEDNESS: single  
(D)TOPOLOGY: linear  
(ix) FEATURE:  
(A)NAME: Peptide  
5 (B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Fmoc-Asp  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:  
Xaa Glu Met Glu Glu Cys Ala Ser His Leu  
1 5 10  
10 (21) INFORMATION FOR SEQ ID NO: 21:  
(i) SEQUENCE CHARACTERISTICS  
(A)LENGTH: 10 amino acids  
(B)TYPE: amino acid  
(C)STRANDEDNESS: single  
15 (D)TOPOLOGY: linear  
(ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp  
20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:  
Xaa Cys Ser Thr Pro Cys Ser Gly Ser Val  
1 5 10  
(22) INFORMATION FOR SEQ ID NO: 22:  
(i) SEQUENCE CHARACTERISTICS  
25 (A)LENGTH: 10 amino acids  
(B)TYPE: amino acid  
(C)STRANDEDNESS: single  
(D)TOPOLOGY: linear  
(ix) FEATURE:  
30 (A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Glu  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:  
Xaa Asp Val Val Cys Cys Ser Met Ser Tyr  
35 1 5 10  
(23) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Ala
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:  
Xaa Glu Met Glu Glu Cys Ala Ser His Leu  
1 5 10
- (24) INFORMATION FOR SEQ ID NO: 24:
- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:  
Xaa Ala Met Glu Glu Cys Ala Ser His Leu  
1 5 10
- (25) INFORMATION FOR SEQ ID NO: 25:
- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
Xaa Glu Ala Glu Glu Cys Ala Ser His Leu

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(D) FURTHER INFORMATION: Xaa is Ac-Asp

**1                  5                  10**

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(D) FURTHER INFORMATION: Xaa is Ac-Asp

**1                      5                      10**

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(D) FURTHER INFORMATION: Xaa is Ac-Asp

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:  
Xaa Glu Met Glu Glu Ala Ala Ser His Leu  
1 5 10
- (29) INFORMATION FOR SEQ ID NO: 29:
- 5 (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- 10 (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
- 15 Xaa Glu Met Glu Glu Cys Ala Ala His Leu  
1 5 10
- (30) INFORMATION FOR SEQ ID NO: 30:
- 20 (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp
- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
- Xaa Glu Met Glu Glu Cys Ala Ser Ala Leu  
1 5 10
- 30 (31) INFORMATION FOR SEQ ID NO: 31:
- (i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- 35 (ix) FEATURE:  
(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Asp

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Xaa Glu Met Glu Glu Cys Ala Ser His Ala

5     1                                 5                                 10

(32) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

10     (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

15     (D) FURTHER INFORMATION: Xaa is Ac-Glu

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Xaa Glu Met Glu Glu Cys Ala Ser His Leu

1                                 5                                 10

(33) INFORMATION FOR SEQ ID NO: 33:

20     (i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25     (ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Asn

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

30     Xaa Glu Met Glu Glu Cys Ala Ser His Leu

1                                 5                                 10

(34) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 10 amino acids

35     (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

- (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Lys
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:  
Xaa Glu Met Glu Glu Cys Ala Ser His Leu  
1 5 10
- (35) INFORMATION FOR SEQ ID NO: 35:  
(i) SEQUENCE CHARACTERISTICS  
10 (A)LENGTH: 10 amino acids  
(B)TYPE: amino acid  
(C)STRANDEDNESS: single  
(D)TOPOLOGY: linear
- (ix) FEATURE:  
15 (A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:  
Xaa Glu Met Glu Glu Cys Ser Ser His Leu  
20 1 - 5 10
- (36) INFORMATION FOR SEQ ID NO: 36:  
(i) SEQUENCE CHARACTERISTICS  
(A)LENGTH: 10 amino acids  
(B)TYPE: amino acid  
25 (C)STRANDEDNESS: single  
(D)TOPOLOGY: linear
- (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 1  
30 (D)FURTHER INFORMATION: Xaa is Ac-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:  
Xaa Glu Met Glu Glu Cys Phe Ser His Leu  
1 5 10
- (37) INFORMATION FOR SEQ ID NO: 37:  
35 (i) SEQUENCE CHARACTERISTICS  
(A)LENGTH: 10 amino acids  
(B)TYPE: amino acid



(C)STRANDEDNESS: single  
(D)TOPOLOGY: linear  
(ix) FEATURE:  
(A)NAME: Peptide  
5 (B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp  
(ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 6  
10 (D)FURTHER INFORMATION: Xaa is Alg  
(alylglycine)  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:  
Xaa Glu Met Glu Glu Xaa Ala Ser His Leu  
1 5 10  
15 (38) INFORMATION FOR SEQ ID NO: 38:  
(i) SEQUENCE CHARACTERISTICS  
(A)LENGTH: 10 amino acids  
(B)TYPE: amino acid  
(C)STRANDEDNESS: single  
20 (D)TOPOLOGY: linear \_  
(ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp  
25 (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 6  
(D)FURTHER INFORMATION: Xaa is Abu ( $\alpha$ -  
amminobutyric acid)  
30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:  
Xaa Glu Met Glu Glu Xaa Ala Ser His Leu  
1 5 10  
(39) INFORMATION FOR SEQ ID NO: 39:  
(i) SEQUENCE CHARACTERISTICS  
35 (A)LENGTH: 10 amino acids  
(B)TYPE: amino acid

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ix) FEATURE:  
(A) NAME: Peptide  
5 (B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:  
Xaa Glu Met Glu Glu Thr Ala Ser His Leu  
1 5 10  
10 (40) INFORMATION FOR SEQ ID NO: 40:  
(i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
15 (D) TOPOLOGY: linear  
(ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp  
20 (ix) FEATURE:  
(A) NAME: Peptide  
(B) POSITION: 6  
(D) FURTHER INFORMATION: Xaa is Nva (norvaline)  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:  
25 Xaa Glu Met Glu Glu Xaa Ala Ser His Leu  
1 5 10  
(41) INFORMATION FOR SEQ ID NO: 41:  
(i) SEQUENCE CHARACTERISTICS  
(A) LENGTH: 10 amino acids  
30 (B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ix) FEATURE:  
(A) NAME: Peptide  
35 (B) POSITION: 1  
(D) FURTHER INFORMATION: Xaa is Ac-Asp  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

Xaa Glu Met Glu Glu Val Ala Ser His Leu

1 5 10

(42) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Asp

(ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 6

(D) FURTHER INFORMATION: Xaa is Abu (2-aminobutyric acid) ester bonded to the following residue

(ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 7

(D) FURTHER INFORMATION: Xaa is Ala ester bonded to the adjacent preceding residue

(ix) FEATURE:

(A) NAME: Peptide

(B) POSITION: 13

(D) FURTHER INFORMATION: Xaa is Lys(N<sup>ε</sup>-Ac)-NH<sub>2</sub>

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Xaa Glu Met Glu Glu Xaa Xaa Ser His Leu Pro Tyr Xaa

1 5 10

(43) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

- (A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp
- (ix) FEATURE:  
5 (A)NAME: Peptide  
(B)POSITION: 6  
(D)FURTHER INFORMATION: Xaa is Thr ester bonded  
to the adjacent following residue
- (ix) FEATURE:  
10 (A)NAME: Peptide  
(B)POSITION: 7  
(D)FURTHER INFORMATION: Xaa is Ala ester bonded  
to the adjacent preceding residue
- (ix) FEATURE:  
15 (A)NAME: Peptide  
(B)POSITION: 13  
(D)FURTHER INFORMATION: Xaa is Lys(N<sup>ε</sup>-Ac)-NH<sub>2</sub>
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:  
Xaa Glu Met Glu Glu Xaa Xaa Ser His Leu Pro Tyr Xaa
- 20 1 5 10  
(44) INFORMATION FOR SEQ ID NO: 44:
- (i) SEQUENCE CHARACTERISTICS  
(A)LENGTH: 13 amino acids  
(B)TYPE: amino acid  
25 (C)STRANDEDNESS: single  
(D)TOPOLOGY: linear
- (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 1  
30 (D)FURTHER INFORMATION: Xaa is Ac-Asp
- (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 6  
(D)FURTHER INFORMATION: Xaa is Abu (2-  
35 aminobutyric acid) ester bonded to the adjacent  
following residue
- (ix) FEATURE:

- 51 -

- (A)NAME: Peptide  
(B)POSITION: 7  
(D)FURTHER INFORMATION: Xaa is Ala ester bonded  
to the adjacent preceding residue
- 5 (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 13  
(D)FURTHER INFORMATION: Xaa is Lys(N<sup>ε</sup>-[<sup>3</sup>H]) -  
CH<sub>3</sub>CO)-NH<sub>2</sub>
- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:  
Xaa Glu Met Glu Glu Xaa Xaa Ser His Leu Pro Tyr Xaa  
1 5 10
- (45) INFORMATION FOR SEQ ID NO: 45:  
(i) SEQUENCE CHARACTERISTICS  
15 (A)LENGTH: 9 amino acids  
(B)TYPE: amino acid  
(C)STRANDEDNESS: single  
(D)TOPOLOGY: linear
- (ix) FEATURE:  
20 (A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp
- (ix) FEATURE:  
(A)NAME: Peptide  
25 (B)POSITION: 3  
(D)FURTHER INFORMATION: Xaa is Asp (EDANS)
- (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 6  
30 (D)FURTHER INFORMATION: Xaa is Abu (2-  
amminobutyric acid) ester bonded to the following  
residue
- (ix) FEATURE:  
(A)NAME: Peptide  
35 (B)POSITION: 7  
(D)FURTHER INFORMATION: Xaa is Ala ester bonded  
to the adjacent preceding residue

- (ix) FEATURE:  
(A)NAME: Peptide  
(B)POSITION: 9  
(D)FURTHER INFORMATION: Xaa is Lys (DABCYL)
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:  
Xaa Glu Xaa Glu Glu Xaa Xaa Ser Xaa  
1 5
- (46) INFORMATION FOR SEQ ID NO: 46:  
(i) SEQUENCE CHARACTERISTICS  
10 (A)LENGTH: 9 amino acids  
(B)TYPE: amino acid  
(C)STRANDEDNESS: single  
(D)TOPOLOGY: linear
- (ix) FEATURE:  
15 (A)NAME: Peptide  
(B)POSITION: 1  
(D)FURTHER INFORMATION: Xaa is Ac-Asp
- (ix) FEATURE:  
20 (A)NAME: Peptide  
(B)POSITION: 2  
(D)FURTHER INFORMATION: Xaa is Asp (EDANS)
- (ix) FEATURE:  
25 (A)NAME: Peptide  
(B)POSITION: 6  
(D)FURTHER INFORMATION: Xaa is Abu (2-  
amminobutyric acid) ester bonded to the following  
residue
- (ix) FEATURE:  
30 (A)NAME: Peptide  
(B)POSITION: 7  
(D)FURTHER INFORMATION: Xaa is Ala ester bonded  
to the adjacent preceding residue
- (ix) FEATURE:  
35 (A)NAME: Peptide  
(B)POSITION: 9  
(D)FURTHER INFORMATION: Xaa is Lys (DABCYL)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Xaa Xaa Met Glu Glu Xaa Xaa Ser Xaa

1

5

(47) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS

5

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

10

(A) NAME: Peptide

(B) POSITION: 1

(D) FURTHER INFORMATION: Xaa is Ac-Asp

(ix) FEATURE:

15

(A) NAME: Peptide

(B) POSITION: 13

(D) FURTHER INFORMATION: Xaa is Lys-ε-(<sup>3</sup>H)Ac

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Xaa Glu Met Glu Glu Cys Ala Ser His Leu Pro Tyr Xaa

1

5

10

CLAIMS

1. Isolated polypeptides, characterised in that they consist of an amino acid sequence chosen from the group comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and in that they have the proteolytic activity of the HCV virus NS3 protein.

2. Expression vectors, for the production of one of the polypeptides according to claim 1 in a host organism, comprising:

10 - a polynucleotide coding for one of said polypeptides;

- functional regulation, transcription and translation sequences within said host organism, operatively bonded to said polynucleotide; and

15 - optionally, a selection marker.

3. Host cell, either eukaryotic or prokaryotic, transformed using an expression vector according to claim 2, capable of expressing the specific polypeptide coded in the chosen polynucleotide sequence.

20 4. A process for preparing one of the polypeptides according to claim 1, characterised by the fact that it comprises, in combination, the following operations:

- transformation of a host cell, either eukaryotic or prokaryotic, using an expression vector containing a DNA sequence coding for a polypeptide chosen from the group of sequences indicated in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5;

25 - expression of the desired DNA sequence to produce the chosen polypeptide; and

30 - purification of the polypeptide thus obtained, avoiding resolubilisation protocols.

5. Peptides, characterised in that they consist of an amino acid sequence chosen from the group of sequences indicated in SEQ ID NOS:7-12, 14, 18-20, 29-32, 35 and 47, and by the fact that they can be used as substrates in a high-throughput assay of the in vitro activity of polypeptides having HCV NS3 proteolytic activity.



6. Depsipeptides, characterised in that they consist of an amino acid sequence chosen from the group of sequences indicated in SEQ ID NOS:42-46, and by the fact that they can be used as substrates in a high-throughput assay of the in vitro activity of polypeptides having HCV NS3 proteolytic activity.


7. A method for reproducing and effectively assaying in vitro the proteolytic activity of the HCV NS3 protein, characterised by the fact that the activity of the polypeptides according to claim 1 is reproduced and tested in a solution containing 30-70 mM Tris pH 6.5-8.5, 3-30 mM dithiotreitol, 0.5-3% 3-[(3-colammide-propyl)-dimethyl-ammonium]-1-propansulphonate and 30-70% glycerol at temperatures of between 20 and 25°C, in a high-throughput assay, using as substrates the peptides of claims 5 or the depsipeptides of claim 6.

8. The method for reproducing and effectively assaying in vitro the proteolytic activity of HCV NS3 according to claim 7, in which the peptides of claim 5 are used in a high-throughput assay at concentrations of the polypeptides according to claim 1 of between 100 and 200 nM.

9. The method for reproducing and effectively assaying in vitro the proteolytic activity of HCV NS3 according to claim 7, in which the depsipeptides of claim 6 are used in a high-throughput assay at concentrations of the polypeptides according to claim 1 of between 0.5 and 2 nM.

10. The method for reproducing and effectively assaying in vitro the proteolytic activity of HCV NS3 according to claim 9, in which continuous monitoring of the proteolytic activity of the polypeptides of claim 1 is carried out by use of depsipeptides chosen from the group of sequences represented by SEQ ID NO: 45 and SEQ ID NO:46 as substrates, with internal fluorogenic quenching by "Resonance Energy Transfer" between a fluorescent donor, 5-[(2'-aminoethyl)amino]naphthalene-

sulfonic acid (EDANS), close to one end of the depsipeptide, and an acceptor group, 4-[[4'-(dimethylaminophenyl)azo]benzoic acid (DABCYL) close to the other end of the depsipeptide.



**P ETL** = promoter of the gene encoding the PCNA protein

**P PH** = polyhedrin promoter

**Amp<sup>r</sup>** = gene encoding β-lactamase (Ampicillin resistance)


**LacZ (β-gal)** = gene encoding β-galactosidase

**Col E1** = pBR322 origin of replication


Fig. 1

2/13

## pT7-7NS3(1039-1226)



## pT7-7NS3(1039-1206)



$\emptyset 10$  =  $\emptyset 10$  promoter of bacteriophage T7

rbs = Shine-Dalgarno ribosome binding sequence

ATG = translation initiation site of the protein encoded by  
by gene 10 of bacteriophage T7


$\beta$ -lactamase = gene encoding  $\beta$ -lactamase (Ampicillin resistance)

Col E1 = pBR322 origin of replication


Fig.2a

3/13

## pT7-7NS3(1027-1206)



## pT7-7NS3(1033-1206)



Ø10 = Ø10 promoter of bacteriophage T7

rbs = Shine-Dalgarno ribosome binding sequence

ATG = translation initiation site of the protein encoded by  
by gene 10 of bacteriophage T7

β-lactamase = gene encoding β-lactamase (Ampicillin resistance)

Col E1 = pBR322 origin of replication

Fig. 2b




Fig.3




Fig. 4




Fig.5




Fig.6

6/13




FIG. 7



7/13




FIG. 8

S1

8/13




FIG. 9

S2

9/13




FIG. 10

10/13






FIG. 11

11/13



Ac-DED(EDANS)EEAbuψ[COO]ASK(DABCYL) S3

FIG. 12



Ac-DD(EDANS)MEEAbuψ[COO]ASK(DABCYL) S4

12/13




FIG. 13




Fig.14a




Fig.14b

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 9/50, C12Q 1/37, C07K 7/06, 7/08, 11/00, 14/18</b>		A3	(11) International Publication Number: <b>WO 97/08304</b>
			(43) International Publication Date: 6 March 1997 (06.03.97)
(21) International Application Number: PCT/IT96/00163		(81) Designated States: AU, BR, CA, CN, JP, RU, US. European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 20 August 1996 (20.08.96)			
(30) Priority Data: RM95A000573 22 August 1995 (22.08.95) IT		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. AN- GELETTI S.P.A. [IT/IT]: Via Pontina, Km 30.600, I-00040 Pomezia (IT).		(88) Date of publication of the international search report: 22 May 1997 (22.05.97)	
(72) Inventors; and (75) Inventors/Applicants (for US only): STEINKÜHLER, Chris- tian [DE/IT]: Via delle Mimose, I-00061 Anguillara (IT). PESSI, Antonello [IT/IT]: Via Montebianco, 63, I-00141 Roma (IT). BIANCHI, Elisabetta [IT/IT]: Via Sabotino, 31, I-00195 Roma (IT). TALIANI, Marina [IT/IT]: Via Curzio Rufo, 15, I-00174 Roma (IT). TOMEI, Licia [IT/IT]: Via Gadda, 173, I-00143 Roma (IT). URBANI, Andrea [IT/IT]: Via Piave, 41, I-00187 Roma (IT). DE FRANCESCO, Raf- faele [IT/IT]: Via Devich, 46, I-00143 Roma (IT). NARJES, Frank [DE/IT]: Via Ramo d'Oro, 53, I-00040 Ariccia (IT).			
(74) Agents: DI CERBO, Mario et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT).			

(54) Title: METHODOLOGY TO PRODUCE, PURIFY AND ASSAY POLYPEPTIDES WITH THE PROTEOLYTIC ACTIVITY OF THE HCV NS3 PROTEASE



(57) Abstract

The process according to the present invention allows expression and isolation of polypeptides with the proteolytic activity of HCV NS3 protease in a pure, catalytically active form, and in amounts that are sufficient for discovery of NS3 protease inhibitors and for determination of the three-dimensional structure of the NS3 protease. A further subject of the present invention is a procedure that defines the chemical and physical conditions necessary for completion of the proteolytic activity of the above polypeptides. The invention further comprises new compositions of matter (expression vectors) containing nucleotide sequences capable of expressing the above mentioned polypeptides in culture cells. Finally, new compounds of matter are defined, suitable to measure the above proteolytic activity, and useful to develop NS3 protease inhibitors and therefore therapeutic agents for use against HCV. The figure shows the kinetic parameters of HCV NS3 protease using the S3 depsiptide substrate (SEQ ID NO:45).



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IT 96/00163

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N9/50 C12Q1/37 C07K7/06 C07K7/08 C07K11/00  
C07K14/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 15575 A (CHIRON CORP) 17 October 1991 Abstract see page 3, line 1 - line 5 see examples 5,6 see claims 1,4,10,16-19,24-26	1-3
A	---	4
X	VIRUS RESEARCH, vol. 23, 1992, pages 39-53, XP000196705 TANAKA T. ET AL.: "Molecular cloning of Hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals" see the whole document ---	1
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

3 April 1997

Date of mailing of the international search report

14. 04. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Panzica, G

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/IT 96/00163

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF CLINICAL INVESTIGATION, vol. 96, 1995, pages 224-230, XP000196704 ENOMOTO N. ET AL.: "Comparison of full length sequences of interferon-sensitive and resistant hepatitis C virus 1b" see the whole document ---	1
X,P	DATABASE WPI Section Ch, Week 9642 Derwent Publications Ltd., London, GB; Class B04, AN 96-419825 XP002028745 & JP 08 205 893 A (SUMITOMO METAL IND LTD) , 13 August 1996 see abstract ---	5,6
E	EP 0 729 973 A (SRL INC., JP) 4 September 1996 see claims 1-10 -----	5,6

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IT 96/00163

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. claims 1- 4: Polypeptides having HCV NS3 proteolytic activity and method for their preparation
2. claims 5-10: Polypeptides to be used as substrates for the assay of the "in vitro" activity of NS3 polypeptides

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 96/00163

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9115575 A	17-10-91	AU 7675491 A	30-10-91
		EP 0527788 A	24-02-93
		PL 169273 B	28-06-96
		US 5585258 A	17-12-96
		US 5371017 A	06-12-94
-----			
EP 0729973 A	04-09-96	AU 8003894 A	22-05-95
		WO 9511918 A	04-05-95
		JP 7179493 A	18-07-95
-----			